Efficacy PotentialThe Ph3 regimen of 100mg loading dose plus 50mg every two weeks could potentially increase drug exposure, possibly boosting its efficacy.

Safety ProfileLoni's safety profile looks promising versus competitors, with no dose-dependent adverse effects seen due to its lower drug concentrations.

Bears Say

Dosing ConcernsConcerns exist on a more frequent dosing interval for lonigutamab versus subcutaneous competition.

Financial ImpactThe price target adjusts from $6 to $5 due to the reduced pipeline spend after removal of uveitis from the model.

Pipeline SetbackAcelyrin's recent announcement that the PhII/III study evaluating izokibep in uveitis did not meet the trial's primary endpoint has led to a reduced sales projection.

ACELYRIN, INC. News

SLRN Upcoming Earnings Report: What to Expect?

ACELYRIN, INC. (SLRN) is scheduled to report 1st quarter earnings on 06/12/2025. Regarding Q1 estimates, Wall Street analysts...

2M ago

SLRN

Two new option listings and two option delistings on May 22nd

New option listings for May 22nd include Galaxy Digital Inc. – Class A common stock (GLXY) and Metsera...

3M ago

MTSR

ACELYRIN Completes Merger and Delists from Nasdaq

ACELYRIN, INC. ( ($SLRN) ) has shared an announcement. On May 21, 2025, ACELYRIN, Inc. completed a merger...

3M ago

SLRN

Alumis completes merger with Acelyrin

Alumis (ALMS) has completed its merger with ACELYRIN (SLRN). Each ACELYRIN stockholder will receive 0.4814 shares of Alumis...

3M ago

ALMS

SLRN

ACELYRIN Stockholders Approve Merger with Alumis

The latest announcement is out from ACELYRIN, INC. ( ($SLRN) ). ACELYRIN, INC., a Delaware corporation, entered into...

3M ago

SLRN

Alumis price target lowered to $25 from $26 at Oppenheimer

Oppenheimer lowered the firm’s price target on Alumis to $25 from $26 and keeps an Outperform rating on...

3M ago

ALMS

SLRN

Acelyrin stockholders approve merger agreement with Alumis

ACELYRIN (SLRN) announced that at the Company’s special meeting of stockholders held earlier, its stockholders voted to approve...

3M ago

ALMS

SLRN

Alumis stockholders approve merger agreement with Acelyrin

Alumis (ALMS) announced that its stockholders voted to approve all proposals required to be approved in connection with...

3M ago

ALMS

SLRN

Acelyrin urges stockholders to vote for proposed merger with Alumis

ACELYRIN (SLRN) reiterated its confidence that the proposed combination with Alumis (ALMS) is the best path forward and...

4M ago

ALMS

SLRN

ACELYRIN, INC. Amends Merger Agreement with Alumis

ACELYRIN, INC. ( ($SLRN) ) just unveiled an announcement. On February 6, 2025, ACELYRIN, INC. entered into a...

4M ago

SLRN

Alumis and Acelyrin sign ammended merger agreement

Alumis (ALMS) and Acelyrin (SLRN) announced an amendment to the existing terms of their previously announced merger agreement:...

4M ago

ALMS

SLRN

SLRN Earnings this Week: How Will it Perform?

ACELYRIN, INC. (SLRN) is scheduled to report 4th quarter earnings on 03/27/2025. Regarding Q4 estimates, Wall Street analysts...

5M ago

SLRN

Acelyrin adopts limited-duration stockholder rights plan

ACELYRIN (SLRN) announced that, in response to Tang Capital Partners’ continued rapid accumulation of 8.8% of ACELYRIN’S outstanding...

5M ago

SLRN

Acelyrin says Concentra indication not expected to result in superior proposal

ACELYRIN (SLRN) announced that, after due consideration in consultation with its independent financial and legal advisors, its Board...

6M ago

ALMS

SLRN

SLRN FAQ

What was ACELYRIN, INC.’s price range in the past 12 months?

ACELYRIN, INC. lowest stock price was $1.84 and its highest was $7.25 in the past 12 months.

What is ACELYRIN, INC.’s market cap?

ACELYRIN, INC.’s market cap is $229.16M.

When is ACELYRIN, INC.’s upcoming earnings report date?

ACELYRIN, INC.’s upcoming earnings report date is Jun 12, 2025 which is 65 days ago.

How were ACELYRIN, INC.’s earnings last quarter?

Currently, no data Available

Is ACELYRIN, INC. overvalued?

According to Wall Street analysts ACELYRIN, INC.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does ACELYRIN, INC. pay dividends?

ACELYRIN, INC. does not currently pay dividends.

What is ACELYRIN, INC.’s EPS estimate?

ACELYRIN, INC.’s EPS estimate is -0.73.

How many shares outstanding does ACELYRIN, INC. have?

ACELYRIN, INC. has 100,954,000 shares outstanding.

What happened to ACELYRIN, INC.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of ACELYRIN, INC.?

Currently, no hedge funds are holding shares in SLRN

ACELYRIN, INC. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-51.08%

Trailing 12-Months

Asset Growth

-37.42%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

ACELYRIN, INC.

ACELYRIN, INC. (SLRN) is a biopharmaceutical company focused on identifying, developing, and commercializing transformative medicines. The company operates in the healthcare sector, specifically targeting unmet medical needs through innovative therapeutic solutions. ACELYRIN is dedicated to advancing a pipeline of drug candidates that address significant health conditions, leveraging cutting-edge research and development to bring new treatments to market.